Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Burel Pharmaceuticals focuses on commercializing a variety of generic and specialty pharmaceutical products, particularly for the US market, including dermatology, CNS, and pain management. The company was acquired by Prasco in 2024 and now operates as a subsidiary, leveraging Prasco’s commercialization platform to launch new generic and niche products, including orphan drugs[4][9].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Burel Pharmaceuticals.